✦ LIBER ✦

Antibody therapy for rheumatoid arthritis

✍ Scribed by Peter C Taylor

Book ID: 117786613
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 229 KB
Volume: 3
Category: Article
ISSN: 1471-4892
DOI: 10.1016/s1471-4892(03)00032-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Humanised monoclonal antibody therapy fo

Humanised monoclonal antibody therapy for rheumatoid arthritis

✍ Isaacs, J.D.; Hale, G.; Cobbold, S.P.; Waldmann, H.; Watts, R.A.; Hazleman, B.L. 📂 Article 📅 1992 🏛 The Lancet 🌐 English ⚖ 696 KB

Candidate targets for antibody therapy o

Candidate targets for antibody therapy of rheumatoid arthritis: CD64 and IL-15

✍ J van de Winkel 📂 Article 📅 2003 🏛 BioMed Central 🌐 English ⚖ 554 KB

Antibodies to mutated citrullinated vime

Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy

✍ Pascale Nicaise Roland, Sabine Grootenboer Mignot… 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 164 KB

Mavrilimumab, a human monoclonal GM-CSF

Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy

✍ Nair, Jagdish R; Edwards, Steven W; Moots, Robert J 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 403 KB

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

Erratum: Golimumab, a human anti-tumor n

Erratum: Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views